# Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes

> **NCT05881837** · PHASE2 · COMPLETED · sponsor: **Fujian Shengdi Pharmaceutical Co., Ltd.** · enrollment: 249 (actual)

## Conditions studied

- Overweight or Obesity

## Interventions

- **DRUG:** HRS9531 injection
- **DRUG:** HRS9531 injection
- **DRUG:** HRS9531 injection
- **DRUG:** HRS9531 injection
- **DRUG:** HRS9531 injection Placebo
- **DRUG:** HRS9531 injection Placebo
- **DRUG:** HRS9531 injection Placebo
- **DRUG:** HRS9531 injection Placebo

## Key facts

- **NCT ID:** NCT05881837
- **Lead sponsor:** Fujian Shengdi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-13
- **Primary completion:** 2024-10-13
- **Final completion:** 2024-10-13
- **Target enrollment:** 249 (ACTUAL)
- **Last updated:** 2025-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05881837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05881837, "Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05881837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*